{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fnucleate-signal.simplecast.com%2Fepisodes%2Fbobby-gaspar-orchard-therapeutics-hPU5rFrI","width":444,"version":"1.0","type":"rich","title":"Pioneering Cell Therapy | Bobby Gaspar, Orchard Therapeutics","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/ed52f7f3-cb55-48af-ae20-82bc5484ef83/a79cf5fe-a623-40da-8d8f-966d626b56de/youtube-20logo.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/f6f6e33c-db79-4055-b4be-441611cecde2\" height=\"200\" width=\"100%\" title=\"Pioneering Cell Therapy | Bobby Gaspar, Orchard Therapeutics\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"This episode is a conversation with Prof Bobby Gaspar, the CEO of Orchard Therapeutics, a clinical stage biotech company developing gene therapies for severe diseases. Signal host Ursule Demael speaks to Prof Bobby Gaspar, who holds an MD/PhD and is an honorary professor of Paediatrics and Immunology at Great Ormond Street Hospital in London (United Kingdom). He has decades of expertise across academic research and biotech developing haematopoietic stem cell therapies for patients with immune deficiencies and metabolic disorders. Orchard’s lead therapy Libmedly is approved for the metabolic disorder MLD in Europe.\n\nOrchard Therapeutics Website: https://www.orchard-tx.com/about/our-story/\n"}